BAYER BENEFITS FROM FOURTH QUARTER PICK-UP

摘要

Bayer says its fourth quarter of 2009 was its best of the year, with Ebitda up 11.5%, to ?1.5 billion ($2 billion), despite a negative cur- rency effect of ?80 million. Sales dipped slightly, to ?7.9 billion, but increased 3% on a currency- and portfolio-adjusted basis. Net income climbed 44.3% to ?153 million compared with fourth quarter 2008. 揙perationally, the fourth quarter was exceptionally successful for Bayer in a year that was otherwise dominated by the crisis,? says Bayer's CFO Klaus K黨n. Fourth-quarter sales at Bayer's HealthCare division grew by 5.9% on a portfolio-adjusted basis, with sales at Bayer CropScience up 6.2% and Bayer MaterialScience up by 1% compared with the same period a year earlier.